MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, PVLA had -$6,866K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$6,866K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-11,345 -17,656
Non-cash interest expense - royalty agreement
1,510 2,569
Non-cash interest expense - convertible note
0 -
Change in fair value of derivative liabilities - royalty agreement
82 193
Change in fair value of derivative liabilities - contingent value right agreement
238 -
Change in fair value of convertible notes payable
0 -
Stock-based compensation
1,790 2,527
Costs to issue convertible notes
0 0
Accounts receivable
0 -358
Prepaid expenses and other current assets
-182 -960
Accounts payable
-1,136 1,240
Accrued expenses and other current liabilities
801 -2,393
Net cash used in operating activities
-7,878 -12,202
Payment of transaction costs in connection with reverse merger
0 1,269
Proceeds from issuance of convertible notes payable
0 0
Payment of transaction costs to issue convertible notes
0 0
Proceeds from exercise of stock options
242 416
Net cash (used in) provided by financing activities
242 -853
Effect of exchange rate change on cash and cash equivalents
770 -114
Net (decrease) increase in cash and cash equivalents
-6,866 -13,169
Cash and cash equivalents at beginning of period
83,602 -
Cash and cash equivalents at end of period
63,567 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

PALVELLA THERAPEUTICS, INC. (PVLA)

PALVELLA THERAPEUTICS, INC. (PVLA)